BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
EPA:BLC - Euronext Paris - Matif - FR0000035370 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to BLC. BLC was compared to 25 industry peers in the Health Care Providers & Services industry. While BLC is still in line with the averages on profitability rating, there are concerns on its financial health. BLC has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
BLC had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BLC (0.25%) is worse than 76.00% of its industry peers.
BLC has a worse Return On Equity (2.25%) than 64.00% of its industry peers.
With a decent Return On Invested Capital value of 5.65%, BLC is doing good in the industry, outperforming 64.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 5.78%.
The 3 year average ROIC (5.34%) for BLC is below the current ROIC(5.65%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROIC | 5.65% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
1.3 Margins
Looking at the Profit Margin, with a value of 0.32%, BLC is doing worse than 72.00% of the companies in the same industry.
Looking at the Operating Margin, with a value of 7.67%, BLC is in line with its industry, outperforming 60.00% of the companies in the same industry.
BLC's Operating Margin has improved in the last couple of years.
BLC's Gross Margin of 67.54% is fine compared to the rest of the industry. BLC outperforms 72.00% of its industry peers.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.67% | ||
| PM (TTM) | 0.32% | ||
| GM | 67.54% |
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
2. Health
2.1 Basic Checks
BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BLC has been reduced compared to 1 year ago.
Compared to 5 years ago, BLC has more shares outstanding
Compared to 1 year ago, BLC has an improved debt to assets ratio.
2.2 Solvency
BLC has an Altman-Z score of 1.43. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BLC (1.43) is worse than 60.00% of its industry peers.
BLC has a debt to FCF ratio of 9.33. This is a negative value and a sign of low solvency as BLC would need 9.33 years to pay back of all of its debts.
The Debt to FCF ratio of BLC (9.33) is comparable to the rest of the industry.
BLC has a Debt/Equity ratio of 5.20. This is a high value indicating a heavy dependency on external financing.
BLC has a Debt to Equity ratio of 5.20. This is amonst the worse of the industry: BLC underperforms 88.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Altman-Z | 1.43 |
ROIC/WACC1.15
WACC4.91%
2.3 Liquidity
BLC has a Current Ratio of 1.19. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
BLC has a Current ratio of 1.19. This is comparable to the rest of the industry: BLC outperforms 60.00% of its industry peers.
BLC has a Quick Ratio of 1.19. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
BLC has a Quick ratio of 0.96. This is comparable to the rest of the industry: BLC outperforms 56.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The earnings per share for BLC have decreased strongly by -71.43% in the last year.
The Revenue has been growing slightly by 3.24% in the past year.
The Revenue has been growing by 9.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
Revenue 1Y (TTM)3.24%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%3.96%
3.2 Future
The Earnings Per Share is expected to grow by 15.74% on average over the next years. This is quite good.
The Revenue is expected to grow by 5.06% on average over the next years.
EPS Next Y9.69%
EPS Next 2Y14.54%
EPS Next 3Y15.74%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y6.99%
Revenue Next 3Y6.96%
Revenue Next 5Y5.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 140.00, BLC can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BLC is valued a bit more expensive than 76.00% of the companies in the same industry.
BLC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.54.
A Price/Forward Earnings ratio of 9.01 indicates a reasonable valuation of BLC.
Based on the Price/Forward Earnings ratio, BLC is valued cheaper than 88.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.44. BLC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 140 | ||
| Fwd PE | 9.01 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaper than 84.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BLC is valued a bit cheaper than 76.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.03 | ||
| EV/EBITDA | 6.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as BLC's earnings are expected to grow with 15.74% in the coming years.
PEG (NY)14.45
PEG (5Y)N/A
EPS Next 2Y14.54%
EPS Next 3Y15.74%
5. Dividend
5.1 Amount
BLC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (7/21/2025, 4:50:54 PM)
30.8
-0.4 (-1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners9.28%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap227.00M
Analysts83.33
Price Target33.66 (9.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-3.5%
DP42.86%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 140 | ||
| Fwd PE | 9.01 | ||
| P/S | 0.42 | ||
| P/FCF | 5.03 | ||
| P/OCF | 2.02 | ||
| P/B | 2.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.13 |
EPS(TTM)0.22
EY0.71%
EPS(NY)3.42
Fwd EY11.1%
FCF(TTM)6.12
FCFY19.86%
OCF(TTM)15.22
OCFY49.4%
SpS73.31
BVpS10.32
TBVpS-19.15
PEG (NY)14.45
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROCE | 8.61% | ||
| ROIC | 5.65% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 10.3% | ||
| OM | 7.67% | ||
| PM (TTM) | 0.32% | ||
| GM | 67.54% | ||
| FCFM | 8.35% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
ROICexc(3y)5.7%
ROICexc(5y)5.58%
ROICexgc(3y)12.68%
ROICexgc(5y)11.8%
ROCE(3y)8.16%
ROCE(5y)7.93%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y1.85%
ROICexc growth 3Y8.09%
ROICexc growth 5Y5.81%
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Debt/EBITDA | 3.72 | ||
| Cap/Depr | 103.59% | ||
| Cap/Sales | 12.41% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.61% | ||
| Profit Quality | 2640.05% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 1.43 |
F-Score6
WACC4.91%
ROIC/WACC1.15
Cap/Depr(3y)89.47%
Cap/Depr(5y)88.81%
Cap/Sales(3y)10.8%
Cap/Sales(5y)10.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
EPS Next Y9.69%
EPS Next 2Y14.54%
EPS Next 3Y15.74%
EPS Next 5YN/A
Revenue 1Y (TTM)3.24%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%3.96%
Revenue Next Year7.14%
Revenue Next 2Y6.99%
Revenue Next 3Y6.96%
Revenue Next 5Y5.06%
EBIT growth 1Y3.82%
EBIT growth 3Y9.86%
EBIT growth 5Y16.32%
EBIT Next Year166.67%
EBIT Next 3Y44.23%
EBIT Next 5YN/A
FCF growth 1Y197.72%
FCF growth 3Y10.22%
FCF growth 5Y6.95%
OCF growth 1Y63.86%
OCF growth 3Y7.62%
OCF growth 5Y8.72%